ES2151185T3 - Lipopoliaminas como agentes de transfeccion y sus aplicaciones farmaceuticas. - Google Patents

Lipopoliaminas como agentes de transfeccion y sus aplicaciones farmaceuticas.

Info

Publication number
ES2151185T3
ES2151185T3 ES96938291T ES96938291T ES2151185T3 ES 2151185 T3 ES2151185 T3 ES 2151185T3 ES 96938291 T ES96938291 T ES 96938291T ES 96938291 T ES96938291 T ES 96938291T ES 2151185 T3 ES2151185 T3 ES 2151185T3
Authority
ES
Spain
Prior art keywords
hydrogen
group
lipopoliamins
whole number
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96938291T
Other languages
English (en)
Inventor
Gerardo Byk
Daniel Scherman
Bertrand Schwartz
Catherine Dubertret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2151185T3 publication Critical patent/ES2151185T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B19/00—Driving, starting, stopping record carriers not specifically of filamentary or web form, or of supports therefor; Control thereof; Control of operating function ; Driving both disc and head
    • G11B19/02—Control of operating function, e.g. switching from recording to reproducing
    • G11B19/04—Arrangements for preventing, inhibiting, or warning against double recording on the same blank or against other recording or reproducing malfunctions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • G11B20/10—Digital recording or reproducing
    • G11B20/18—Error detection or correction; Testing, e.g. of drop-outs
    • G11B20/1816—Testing
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • G11B20/10—Digital recording or reproducing
    • G11B20/18—Error detection or correction; Testing, e.g. of drop-outs
    • G11B20/1866—Error detection or correction; Testing, e.g. of drop-outs by interleaving
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • G11B20/24—Signal processing not specific to the method of recording or reproducing; Circuits therefor for reducing noise
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • G11B20/10—Digital recording or reproducing
    • G11B20/10009—Improvement or modification of read or write signals
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • G11B20/10—Digital recording or reproducing
    • G11B20/12—Formatting, e.g. arrangement of data block or words on the record carriers
    • G11B20/1217—Formatting, e.g. arrangement of data block or words on the record carriers on discs
    • G11B20/1258—Formatting, e.g. arrangement of data block or words on the record carriers on discs where blocks are arranged within multiple radial zones, e.g. Zone Bit Recording or Constant Density Recording discs, MCAV discs, MCLV discs
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • G11B20/10—Digital recording or reproducing
    • G11B20/14—Digital recording or reproducing using self-clocking codes
    • G11B20/1403—Digital recording or reproducing using self-clocking codes characterised by the use of two levels
    • G11B2020/1476—Synchronisation patterns; Coping with defects thereof
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • G11B20/10—Digital recording or reproducing
    • G11B20/18—Error detection or correction; Testing, e.g. of drop-outs
    • G11B20/1816—Testing
    • G11B2020/183—Testing wherein at least one additional attempt is made to read or write the data when a first attempt is unsuccessful

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A LIPOPOLIAMINAS DE FORMULA (I) EN LAS CUALES R1, R2 Y R3 REPRESENTAN INDEPENDIENTEMENTE UN ATOMO DE HIDROGENO O UN GRUPO (CH2)Q NRR , EN DONDE Q ES 1, 2, 3, 4, 5, O 6 PARA CADA UNO DE LOS GRUPOS R1, R2 Y R3; SIENDO M, N Y P, QUE PUEDEN SER IGUALES O DIFERENTES, UN NUMERO ENTERO ENTRE 0 Y 6; R4 ES UN GRUPO DE LA FORMULA GENERAL (II), EN DONDE R6 Y R7, QUE PUEDEN SER IGUALES O DIFERENTES, ES UN ATOMO DE HIDROGENO O UN RADICAL ALIFATICO C10-22 SATURADO O INSATURADO SIENDO AL MENOS UNO DE LOS DOS GRUPOS DIFERENTES AL HIDROGENO; U ES UN NUMERO ENTERO ENTRE 0 Y 10, X ES UN ATOMO DE OXIGENO O DE AZUFRE O UN GRUPO AMINA OPCIONALMENTE MONOALQUILADO, Y ES UN GRUPO CARBONILO O METILENO, R5 ES UN ATOMO DE HIDROGENO O UNA CADENA LATERAL DE AMINOACIDO NATURAL OPCIONALMENTE SUSTITUIDA Y R ES UN NUMERO ENTERO ENTRE 1 Y 10, CON LA CONDICION DE QUE CUANDO R ES 1, R5 ES UNA CADENA LATERAL DE AMINOACIDO NATURAL OPCIONALMENTE SUSTITUIDA, Y CUANDO R ES SUPERIOR A 1, R5 ES UN ATOMO DE HIDROGENO. LA INVENCION SE REFIERE ASIMISMO A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTAS LIPOPOLIAMINAS Y AL USO DE LAS MISMAS PARA LA TRANSFECCION IN VITRO O IN VIVO DE ACIDO NUCLEICO EN CELULAS.
ES96938291T 1995-11-14 1996-11-08 Lipopoliaminas como agentes de transfeccion y sus aplicaciones farmaceuticas. Expired - Lifetime ES2151185T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9513490A FR2741066B1 (fr) 1995-11-14 1995-11-14 Nouveaux agents de transfection et leurs applications pharmaceutiques

Publications (1)

Publication Number Publication Date
ES2151185T3 true ES2151185T3 (es) 2000-12-16

Family

ID=9484558

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96938291T Expired - Lifetime ES2151185T3 (es) 1995-11-14 1996-11-08 Lipopoliaminas como agentes de transfeccion y sus aplicaciones farmaceuticas.

Country Status (23)

Country Link
US (1) US6171612B1 (es)
EP (1) EP0861228B1 (es)
JP (2) JP4176831B2 (es)
KR (1) KR19990067552A (es)
AT (1) ATE195721T1 (es)
AU (1) AU718568B2 (es)
BR (1) BR9611533A (es)
CA (1) CA2235721C (es)
CZ (1) CZ147398A3 (es)
DE (1) DE69609982T2 (es)
DK (1) DK0861228T3 (es)
ES (1) ES2151185T3 (es)
FR (1) FR2741066B1 (es)
GR (1) GR3034204T3 (es)
HU (1) HUP9900605A3 (es)
IL (1) IL124411A (es)
MX (1) MX9803761A (es)
NO (1) NO981944D0 (es)
PT (1) PT861228E (es)
SI (1) SI0861228T1 (es)
SK (1) SK282173B6 (es)
WO (1) WO1997018185A1 (es)
ZA (1) ZA969489B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756491B1 (fr) * 1996-11-29 1999-01-08 Rhone Poulenc Rorer Sa Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
FR2750704B1 (fr) 1996-07-04 1998-09-25 Rhone Poulenc Rorer Sa Procede de production d'adn therapeutique
US6884430B1 (en) * 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
CA2305575A1 (en) * 1997-09-08 1999-03-18 Valentis, Inc. Hydrophobic glycosylamine derivatives, compositions, and methods for use
EP1049793B1 (fr) 1998-01-30 2005-10-12 Aventis Pharma S.A. Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
FR2774394B1 (fr) * 1998-01-30 2002-04-26 Rhone Poulenc Rorer Sa Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
JP2002513543A (ja) * 1998-04-02 2002-05-14 アバンテイス・フアルマ・エス・アー 新規核酸移入剤とそれらを含む組成物及びそれらの使用
FR2777017B1 (fr) * 1998-04-02 2002-08-23 Rhone Poulenc Rorer Sa Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications
AU768542C (en) 1998-04-08 2004-06-17 Celltech R & D Limited Lipids
GB9914045D0 (en) 1999-06-16 1999-08-18 Smithkline Beecham Plc Novel compounds
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
GB9919338D0 (en) * 1999-08-16 1999-10-20 Celltech Therapeutics Ltd Biological products
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
EP1383492A4 (en) * 2001-03-23 2008-12-24 Napro Biotherapeutics Inc MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY
AU2002257904B2 (en) * 2001-05-14 2007-12-06 Gencell S.A. Polythiourea lipid derivatives
FR2824557B1 (fr) * 2001-05-14 2003-08-29 Aventis Pharma Sa Derives lipidiques de polythiouree
AUPR621501A0 (en) * 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
EP1430074B1 (fr) * 2001-08-29 2009-05-06 Aventis Pharma S.A. Derives lipidiques d'aminoglycosides-pour la transfection
AU2003205545A1 (en) 2002-01-17 2003-07-30 York Refrigeration Aps Submerged evaporator with integrated heat exchanger
ES2328031T3 (es) * 2002-05-24 2009-11-06 F. Hoffmann-La Roche Ag Composiciones para distribuir acidos nucleicos a celulas.
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
EP2476756A1 (en) * 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
CA2665403C (en) * 2006-10-04 2015-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
WO2008137470A1 (en) * 2007-05-01 2008-11-13 Pgr-Solutions Multi-chain lipophilic polyamines
WO2010026537A1 (en) 2008-09-05 2010-03-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel multimodular assembly useful for intracellular delivery
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
FR2941152B1 (fr) 2009-01-20 2013-10-18 Centre Nat Rech Scient Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
JP2014508102A (ja) * 2010-11-15 2014-04-03 ライフ テクノロジーズ コーポレーション アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2013016058A1 (en) * 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
KR20150000461A (ko) 2011-10-27 2015-01-02 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
CZ201220A3 (cs) * 2012-01-13 2013-07-17 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Lipopolyaminy sperminového typu pro konstrukci liposomálních transfekcních systému
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
EP4342978A3 (en) 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Gold optimized car t-cells
EP3580212A4 (en) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
MX2020002872A (es) 2017-09-15 2020-10-05 Commw Scient Ind Res Org Moléculas de arn.
US20240216509A1 (en) 2018-05-07 2024-07-04 Children's Hospital Medical Center Chimeric polypeptides, nucleic acid molecules, cells, and related methods
JPWO2020213724A1 (es) 2019-04-19 2020-10-22
JPWO2020246563A1 (es) 2019-06-05 2020-12-10
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
US20240150472A1 (en) 2021-03-17 2024-05-09 Daiichi Sankyo Company, Limited Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
US20240366666A1 (en) 2021-04-08 2024-11-07 Phosphogam, Llc Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells
WO2024150525A1 (ja) 2023-01-12 2024-07-18 国立大学法人山口大学 抗ネコｐｄ－１抗体
WO2025080209A1 (en) * 2023-10-10 2025-04-17 Agency For Science, Technology And Research A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211692A (en) * 1961-11-06 1965-10-12 Gulf Oil Corp Ethylene polymeric compositions containing substituted ureas
US3965015A (en) * 1972-08-01 1976-06-22 Colgate-Palmolive Company Bleach-resistant fabric softener
DE2355026A1 (de) * 1973-11-03 1975-05-15 Henkel & Cie Gmbh Neue omega-amino-carbonsaeureamide, deren herstellung, sowie verwendung als antimikrobielle mittel
FR2369837A1 (fr) * 1976-11-04 1978-06-02 Labaz Derives actifs de l'uree, leur procede de preparation ainsi que les compositions therapeutiques les contenant
JPS60123451A (ja) * 1983-12-07 1985-07-02 Eisai Co Ltd ポリプレニル系化合物およびその製造方法ならびにそれを含有する医薬
CA1280414C (en) * 1985-03-15 1991-02-19 Saichi Matsumoto Isoprenoidamine derivatives and antiulcer agents
US4828982A (en) * 1985-05-28 1989-05-09 Becton, Dickinson & Company Vesticles and use thereof in an enzyme assay
CA1335686C (fr) * 1986-01-13 1995-05-23 Rao K. S. P. Bhushana Vinblastine et composition pharmaceutique les contenant
JPS6480282A (en) * 1987-09-22 1989-03-27 Nippon Oils & Fats Co Ltd Nonaqueous highly active enzyme
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
JP2720167B2 (ja) * 1988-04-11 1998-02-25 日本ケミファ株式会社 アルキレンジアミン誘導体
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
EP0410169B1 (de) * 1989-07-28 1994-12-14 Chemie Linz GmbH Verfahren zur Herstellung unsymmetrisch substituierter Harnstoffe, Carbamate, Thiocarbamate und substituierter Isocyanate
JP2620727B2 (ja) * 1990-10-26 1997-06-18 富士写真フイルム株式会社 ペプチド脂質
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations

Also Published As

Publication number Publication date
CA2235721A1 (fr) 1997-05-22
ATE195721T1 (de) 2000-09-15
NO981944L (no) 1998-04-29
JP2009029790A (ja) 2009-02-12
GR3034204T3 (en) 2000-11-30
US6171612B1 (en) 2001-01-09
JP4176831B2 (ja) 2008-11-05
IL124411A (en) 2001-09-13
AU718568B2 (en) 2000-04-13
JP4999784B2 (ja) 2012-08-15
DK0861228T3 (da) 2000-10-23
NO981944D0 (no) 1998-04-29
FR2741066A1 (fr) 1997-05-16
SI0861228T1 (en) 2000-12-31
JP2000501383A (ja) 2000-02-08
MX9803761A (es) 1998-09-30
ZA969489B (en) 1997-06-02
SK63198A3 (en) 1998-11-04
DE69609982T2 (de) 2001-01-25
BR9611533A (pt) 1999-07-13
IL124411A0 (en) 1998-12-06
FR2741066B1 (fr) 1997-12-12
KR19990067552A (ko) 1999-08-25
CA2235721C (fr) 2009-07-14
CZ147398A3 (cs) 1998-08-12
EP0861228B1 (fr) 2000-08-23
HUP9900605A3 (en) 1999-11-29
WO1997018185A1 (fr) 1997-05-22
HUP9900605A2 (hu) 1999-06-28
PT861228E (pt) 2001-02-28
AU7576896A (en) 1997-06-05
DE69609982D1 (de) 2000-09-28
SK282173B6 (sk) 2001-11-06
EP0861228A1 (fr) 1998-09-02

Similar Documents

Publication Publication Date Title
GT199700015A (es) Inhibidores de metaloproteinasa, composiciones farmaceuticas que las contienen y su uso farmaceutico y metodosyeficazproducto intermedio para su preparacion.
MX9803761A (es) Nuevos agentes de transfeccion y sus aplicaciones farmaceuticas.
PA8439101A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
GT199800046A (es) Compuestos de pirazina.
TW365602B (en) New farnesyl transferase inhibitors, their preparation and the pharmaceutical compositions which contain them
ATE216590T1 (de) Arzneimittelformulierungen für il-12
PA8442201A1 (es) Derivados de 6-fenilpiridil-2-amina
ES2098790T3 (es) Derivados de 1,2,3,5,6,7,8,8a-octahidro-5,5,8a-trimetil-(8abeta)-6-isoquinoleinamina, su procedimiento de preparacion y su empleo en terapeutica.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2104946T3 (es) Ureas ciclicas y similares utiles como inhibidores de la proteasa retrovirica.
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
ES2196377T3 (es) Derivados de naftiridina.
ES2061546T3 (es) Compuestos quelantes de piridoxamina, quelatos de manganeso (ii) y su uso como agentes de contraste de nmri.
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ES2171923T3 (es) Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.
ES2065324T3 (es) N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos.
ES2154318T3 (es) Agentes antitromboticos.
ES2147427T3 (es) Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
TR199900945T2 (xx) Matriks metaloproteaz �nleyiciler olarak ikameli 4-bifenil-4-hidroksib�tirik asit t�revleri.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2179864T3 (es) 4-benzoil-isoxazoles y su uso como herbicidas.
AR028947A1 (es) Compuestos novedosos
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2081144T3 (es) Amidas de aminoacidos substituidas.
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 861228

Country of ref document: ES